Shanghai Shen Lian Biomedical Corporation

Shanghai Stock Exchange 688098.SS

Shanghai Shen Lian Biomedical Corporation Free Cash Flow for the year ending December 31, 2023: USD -17.76 M

Shanghai Shen Lian Biomedical Corporation Free Cash Flow is USD -17.76 M for the year ending December 31, 2023, a -45.86% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Shanghai Shen Lian Biomedical Corporation Free Cash Flow for the year ending December 31, 2022 was USD -12.18 M, a 21.08% change year over year.
Shanghai Shen Lian Biomedical Corporation Free Cash Flow for the year ending December 31, 2021 was USD -15.43 M, a -94.32% change year over year.
Shanghai Shen Lian Biomedical Corporation Free Cash Flow for the year ending December 31, 2020 was USD -7.94 M, a -9.99% change year over year.
Shanghai Shen Lian Biomedical Corporation Free Cash Flow for the year ending December 31, 2019 was USD -7.22 M, a -217.31% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Shanghai Stock Exchange: 688098.SS

Shanghai Shen Lian Biomedical Corporation

CEO	Mr. Dongsheng Nie
IPO Date	Oct. 28, 2019
Location	China
Headquarters	No. 48 Jiangchuan East Road
Employees	380
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.

Key trends

Past 5 years